Tevogen Bio(TVGNW)

Focus: Tevogen Bio is a public biotechnology company focused on T cell therapy development, particularly for COVID-19 and oncology applications. The company operates as a pre-revenue stage biotech with early-stage clinical programs.

Oncology Infectious Diseases Gene Therapy Cell Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Tevogen Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Tevogen Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cytotoxic T Lymphocytes

Covid19

PHASE_1

Clinical Trials (1)

NCT04765449Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Phase 1

Help build intelligence for Tevogen Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage T cell therapy platform with potential to establish foundational IP in cell-based immunotherapy — ground-floor opportunity in high-growth modality
Public company status provides liquidity and institutional credibility, reducing startup risk relative to private cell therapy companies
Therapeutic focus across oncology and infectious disease offers long-term diversification beyond COVID indication

Watch Out For

Pre-revenue stage with negative net income of $13.7M in FY2025 and $60.5M in FY2024 signals significant cash burn and sustainability questions
Only one Phase 1 program in active development with no Phase 2+ programs — extremely early clinical validation and long time to market
Zero active job openings and no headcount data suggests minimal hiring and possible capital constraints limiting career growth opportunities

Generated by Claude from Tevogen Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Infectious Diseases

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

1 pipeline

Marketed

Pipeline

Financials (FY2025)

R&D Spend

$31M605%

Net Income

-$14M

Cash

Source: SEC 10-K Filing